Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease (DKD) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report outlays ...
In addition to AIS, DiaMedica (DMA.V) (DMCAF) is also developing DM199 for the treatment of diabetic kidney disease (DKD). Diabetic kidney disease (DKD) or Diabetic nephropathy (DN) is one of the most ...
George L. Bakris, MD, describes the design and results of the FIDELIO-DKD trial investigating the effect of finerenone on patients with chronic kidney disease. Neil B. Minkoff, MD: Dr Bakris, I ...
Key opinion leaders discuss the clinical significance of dosing flexibility for the CANDOR trial regimen, as studied in the EQUULEUS trial. C. Ola Landgren, MD, PhD: The once-weekly and twice-weekly ...
Among patients with diabetic kidney disease (DKD), those with anemia may especially reap cardiovascular benefits from finerenone treatment. Finerenone treatment reduces cardiovascular and kidney risks ...
In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD). The objective of the Phase IIb study was to evaluate the ...
DKD remains a large unmet medical need. Professor Coward, discussing the project, said: “ BEAt-DKD will study thousands of patients affected with DKD across Europe. We hope to discover key factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results